Clinical pharmacokinetics of new antiepileptic drugs.
Article Details
- CitationCopy to clipboard
Walker MC, Patsalos PN
Clinical pharmacokinetics of new antiepileptic drugs.
Pharmacol Ther. 1995;67(3):351-84.
- PubMed ID
- 8577822 [ View in PubMed]
- Abstract
We have reviewed the pharmacokinetics of six antiepileptic drugs that are marketed (felbamate, gabapentin, lamotrigine, oxcarbazepine, vigabatrin, and zonisamide) and six drugs that are undergoing evaluation (levetiracetam, ralitoline, remacemide, stiripentol, tiagabine, and topiramate). In addition, we have compared the prodrugs eterobarb and fosphenytoin and the controlled-release formulations of valproic acid and carbamazepine with their parent compounds. Finally, we have devised a scoring system to compare the pharmacokinetics of new antiepileptic drugs. Using this system, vigabatrin, levetiracetam, gabapentin, and topiramate appea to have the most favourable pharmacokinetic profiles, whilst ralitoline and stiripentol have the least favourable.
DrugBank Data that Cites this Article
- Drug Carriers
Drug Carrier Kind Organism Pharmacological Action Actions Fosphenytoin Serum albumin Protein Humans NoOther/unknownDetails